Elsevier

Biochemical Pharmacology

Volume 74, Issue 8, 15 October 2007, Pages 1299-1307
Biochemical Pharmacology

Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats

https://doi.org/10.1016/j.bcp.2007.05.020Get rights and content

Abstract

Glutamate neurotransmission, and particularly metabotropic glutamate (mGlu) 2/3 receptors are implicated in behaviors of relevance to the addictive properties of nicotine. In laboratory animals, the mGlu2/3 receptor agonist LY379268 has been previously shown to decrease intravenous nicotine self-administration and cue-induced reinstatement of nicotine-seeking behavior. Such mGlu2/3 receptor agonists may therefore be useful medications to assist people in smoking cessation. Because of the demonstrated preclinical efficacy of mGlu2/3 receptor agonists in decreasing the primary rewarding and conditioned effects of nicotine in rats, we wished to examine whether such compounds could potentially influence additional aspects of nicotine dependence, such as nicotine withdrawal. We hypothesized that an mGlu2/3 receptor agonist would have negative effects on nicotine withdrawal because mGlu2/3 receptor antagonists have previously been shown to attenuate nicotine withdrawal-induced reward deficits, while an mGlu2/3 receptor agonist precipitated withdrawal-like reward deficits in rats dependent on nicotine. To test this hypothesis, we assessed the effects of the mGlu2/3 receptor agonist LY379268 on brain reward deficits associated with spontaneous nicotine withdrawal in rats. Brain reward function, as assessed by intracranial self-stimulation reward thresholds, was examined after removal of nicotine- or saline-delivering subcutaneous osmotic minipumps. LY379268 administration produced reward deficits in animals “withdrawing” from chronic saline administration and only tended to aggravate nicotine withdrawal-induced reward deficits in rats previously treated with nicotine. Thus, this mGlu2/3 agonist does not appear to significantly influence the affective depression-like aspects of nicotine withdrawal.

Introduction

Nicotine withdrawal produces negative affective symptoms in humans, including depressed mood, irritability, craving, and anxiety [1], [2], [3]. This aversive abstinence syndrome in smokers is thought to contribute to the persistence of the tobacco smoking habit and relapse during abstinence [4], [5]. In animals, nicotine withdrawal precipitates a deficit in brain reward function, as measured by elevations in reward thresholds for intracranial self-stimulation (ICSS), similar to those observed in rats undergoing withdrawal from other major drugs of abuse [6]. In addition, a somatic nicotine withdrawal syndrome has been characterized in rats, including somatic signs such as abdominal constrictions (writhes), gasps, foot licks, and eyeblinks [6], [7], [8].

Metabotropic glutamate (mGlu) 2/3 receptors are presynaptic inhibitory autoreceptors that negatively modulate excitatory glutamate transmission [9]. LY379268 is a heterobicyclic amino acid and selective mGlu2/3 receptor agonist. LY379268 is highly selective for the presynaptic mGlu2 and mGlu3 receptor subtypes as compared to other glutamate receptors including N-methyl-d-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), kainate, and other mGlu receptors [10].

mGlu2/3 receptor agonists reduce brain glutamate transmission, thereby indirectly reducing dopamine levels in the nucleus accumbens [11]. Both reduced glutamate and dopamine transmission play a role in depression and withdrawal from drugs of abuse [12], [13], [14]. Accordingly, mGlu2/3 receptor antagonists that increase glutamate and dopamine neurotransmission have been suggested as potential treatments for depression and depressive symptoms associated with drug-withdrawal [13], [14]. Consistent with this hypothesis, mGlu2/3 receptor antagonists had antidepressant-like effects in the rat forced swim test [15], the mouse tail suspension test [15], and the learned helplessness procedure in rats [16], prevented stress-induced autonomic hyperactivity [17], and attenuated reward deficits associated with spontaneous nicotine withdrawal in rats [18]. In contrast, the mGlu2/3 receptor agonist LY314582 precipitated withdrawal-like reward deficits in nicotine-dependent rats while nicotine was on board [18]. Taken together, these data suggest that mGlu2/3 receptor antagonists may be used to treat depression and depressive symptoms during nicotine withdrawal.

However, mGlu2/3 receptor agonists have also been suggested for the treatment of drug dependence based on their well-documented potential to reduce drug reward and reinstatement of drug-seeking behavior that was previously extinguished. In particular, the mGlu2/3 receptor agonist LY379268 reduced self-administration of cocaine, ethanol, and nicotine and prevented reinstatement of drug-seeking behavior for cocaine, ethanol, heroin, and nicotine [19], [20], [21], [22], [23], [24], [25]. While many recent studies have assessed the beneficial effects of the mGlu2/3 receptor agonist LY379268 in decreasing drug reward and drug-seeking behavior, little if any work has assessed whether mGlu2/3 receptor stimulation may have adverse effects on the reward system during spontaneous drug withdrawal. Because the mGlu2/3 receptor antagonist LY341495 reversed brain reward deficits associated with nicotine withdrawal and the mGlu2/3 agonist LY314582 precipitated nicotine withdrawal-like reward deficits in rats under chronic nicotine treatment, we hypothesized that the mGlu2/3 receptor agonist LY379268 would increase reward deficits associated with spontaneous nicotine withdrawal in rats.

Section snippets

Subjects

Male Wistar rats (Charles River, Raleigh, NC) weighing 300–350 g upon arrival in the laboratory were group housed (two per cage throughout the duration of the study) in a temperature- and humidity-controlled vivarium on a 12 h reverse light–dark cycle (lights off at 8 a.m.). All behavioral testing took place during the dark phase of the light–dark cycle. After arrival in the vivarium, animals were allowed to habituate to their new environment for 1 week and were handled twice during that time.

Effect of LY379268 on brain reward thresholds under baseline conditions

Mean ± S.E.M. baseline thresholds during Session 1 were 106 ± 7 μA. LY379268 elevated intracranial self-stimulation thresholds [F(2,22) = 4.8, p < 0.02]. The dose of 3 mg/kg LY379268 significantly elevated reward thresholds (p < 0.001), while the 1 mg/kg dose induced a non-significant elevation (Fig. 1). Mean ± S.E.M. baseline response latencies during Session 1 were 3.36 ± 0.13 s before vehicle injection, 3.14 ± 0.12 s before the 1 mg/kg LY379268 dose injection, and 3.14 ± 0.15 s before the 3 mg/kg LY379268 dose

Discussion

Spontaneous nicotine withdrawal elevated ICSS thresholds, indicating a deficit in reward function consistent with previous findings [6]. Elevations in ICSS reward thresholds observed in rats during nicotine withdrawal are considered a model of the affective depression-like aspects of nicotine withdrawal in humans, and more specifically of the symptom of anhedonia [4], [6], [31]. Contrary to our hypothesis that the mGlu2/3 receptor agonist would aggravate this reward deficit, LY379268 did not

Acknowledgements

This work was supported by National Institute on Drug Abuse grant DA11946 to AM. M.E.L was supported by fellowship awards from the Swiss National Science Foundation (SNF-PBZHB-108501, SSMBS 1246 and F. Hofmann-La Roche Ltd., Basel, Switzerland). The authors would like to thank Dr. Neil E. Paterson for comments on the manuscript, Ms. Jessica Benedict for technical assistance, and Mr. Mike Arends for editorial assistance.

References (47)

  • A. Markou et al.

    Neurobiological similarities in depression and drug dependence: a self-medication hypothesis

    Neuropsychopharmacology

    (1998)
  • P. Backstrom et al.

    Suppression of alcohol self-administration and cue-induced reinstatement of alcohol seeking by the mGlu2/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)-3,4-DCPG

    Eur J Pharmacol

    (2005)
  • B.E. Hildebrand et al.

    Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome

    Brain Res

    (1998)
  • M.E. Liechti et al.

    Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats

    Eur J Pharmacol

    (2007)
  • A.Y. Bespalov et al.

    Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats

    Neuropharmacology

    (2005)
  • J.R. Hughes et al.

    Signs and symptoms of tobacco withdrawal

    Arch Gen Psychiatry

    (1986)
  • Diagnostic and statistical manual of mental disorders

    (1994)
  • J.R. Hughes et al.

    Symptoms of tobacco withdrawal. A replication and extension

    Arch Gen Psychiatry

    (1991)
  • S. Shiffman et al.

    Progression from a smoking lapse to relapse: prediction from abstinence violation effects, nicotine dependence, and lapse characteristics

    J Consult Clin Psychol

    (1996)
  • M.P. Epping-Jordan et al.

    Dramatic decreases in brain reward function during nicotine withdrawal

    Nature

    (1998)
  • D.D. Schoepp

    Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system

    J Pharmacol Exp Ther

    (2001)
  • J.A. Monn et al.

    Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors

    J Med Chem

    (1999)
  • T. Yoshimizu et al.

    An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats

    Psychopharmacology (Berl)

    (2006)
  • Cited by (29)

    • Effects of Methamphetamine Self-Administration and Extinction on Astrocyte Structure and Function in the Nucleus Accumbens Core

      2019, Neuroscience
      Citation Excerpt :

      As such, reduced tonic activation of mGluR2/3 in the NAcore is an important aspect of the molecular basis of methamphetamine relapse vulnerability, as this adaptation would serve to exacerate glutamate release during drug seeking, discussed in detail below. Consistent with this hypothesis, systemic activation of mGluR2/3 has been shown to inhibit cued methamphetamine (Kufahl et al., 2013; Caprioli et al., 2015), cocaine (Peters and Kalivas, 2006), nicotine (Liechti and Markou, 2007), heroin (Bossert et al., 2005), and ethanol seeking (Zhao et al., 2006). Further, xCT, the catalytic subunit of xC-, is downregulated in the NAcore following cocaine (Knackstedt et al., 2010) and nicotine (Knackstedt et al., 2009) self-administration (SA) and extinction.

    • Enhancing glutamatergic transmission during adolescence reverses early-life stress-induced deficits in the rewarding effects of cocaine in rats

      2015, Neuropharmacology
      Citation Excerpt :

      Thus, early-life stress can impact greatly on the development of neuronal signalling systems via glutamatergic mechanisms. Previous studies have shown that inhibiting glutamatergic neurotransmission through AMPA or NMDA receptor blockade (Bisaga et al., 2000; Gass and Olive, 2008) or through inhibiting signalling via mGlu receptor manipulation (Heilig and Egli, 2006; Lea and Faden, 2006; Li et al., 2010, 2013; Liechti and Markou, 2007; Moussawi and Kalivas, 2010) can block the reinforcing effects of cocaine. Furthermore, one mechanism put forward to explain the therapeutic mechanism of antidepressant drugs is the inhibition of stress-induced glutamate release (Musazzi et al., 2013).

    View all citing articles on Scopus
    View full text